These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

237 related articles for article (PubMed ID: 1606355)

  • 21. The effect of age, sex, and rifampin administration on intestinal and hepatic cytochrome P450 3A activity.
    Gorski JC; Vannaprasaht S; Hamman MA; Ambrosius WT; Bruce MA; Haehner-Daniels B; Hall SD
    Clin Pharmacol Ther; 2003 Sep; 74(3):275-87. PubMed ID: 12966371
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of human cytochrome P(450)s that metabolise anti-parasitic drugs and predictions of in vivo drug hepatic clearance from in vitro data.
    Li XQ; Björkman A; Andersson TB; Gustafsson LL; Masimirembwa CM
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):429-42. PubMed ID: 12920490
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Changes in pharmacokinetics in elderly patients].
    Nadai M; Katoh M
    Nihon Rinsho; 2013 Jun; 71(6):999-1003. PubMed ID: 23855202
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ontogeny of hepatic and renal systemic clearance pathways in infants: part II.
    Alcorn J; McNamara PJ
    Clin Pharmacokinet; 2002; 41(13):1077-94. PubMed ID: 12403644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Old age and the hepatic sinusoid.
    Le Couteur DG; Warren A; Cogger VC; Smedsrød B; Sørensen KK; De Cabo R; Fraser R; McCuskey RS
    Anat Rec (Hoboken); 2008 Jun; 291(6):672-83. PubMed ID: 18484614
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fasting-Induced Changes in Hepatic P450 Mediated Drug Metabolism Are Largely Independent of the Constitutive Androstane Receptor CAR.
    de Vries EM; Lammers LA; Achterbergh R; Klümpen HJ; Mathot RA; Boelen A; Romijn JA
    PLoS One; 2016; 11(7):e0159552. PubMed ID: 27434302
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recent developments in hepatic drug oxidation. Implications for clinical pharmacokinetics.
    Brosen K
    Clin Pharmacokinet; 1990 Mar; 18(3):220-39. PubMed ID: 2182263
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Age-related changes in hepatic expression and activity of cytochrome P450 in male rats.
    Yun KU; Oh SJ; Oh JM; Kang KW; Myung CS; Song GY; Kim BH; Kim SK
    Arch Toxicol; 2010 Dec; 84(12):939-46. PubMed ID: 20130842
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Liver function assessment by drug metabolism.
    Barstow L; Small RE
    Pharmacotherapy; 1990; 10(4):280-8. PubMed ID: 2388874
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of human drug clearance by multiple metabolic pathways: integration of hepatic and intestinal microsomal and cytosolic data.
    Cubitt HE; Houston JB; Galetin A
    Drug Metab Dispos; 2011 May; 39(5):864-73. PubMed ID: 21303923
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics in the elderly.
    Crooks J; O'Malley K; Stevenson IH
    Clin Pharmacokinet; 1976; 1(4):280-96. PubMed ID: 797500
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The physiologic basis for clearance measurements in hepatology.
    Winkler K; Bass L; Keiding S; Tygstrup N
    Scand J Gastroenterol; 1979; 14(4):439-48. PubMed ID: 482856
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Relationship between metabolic clearance rate of antipyrine and hepatic microsomal drug-oxidizing enzyme activities in humans without liver disease.
    Vuitton D; Miguet JP; Camelot G; Delafin C; Joanne C; Bechtel P; Gillet M; Carayon P
    Gastroenterology; 1981 Jan; 80(1):112-8. PubMed ID: 7450397
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical pharmacology and aging].
    Lafuente-Lafuente C; Baudry E; Paillaud E; Piette F
    Presse Med; 2013 Feb; 42(2):171-80. PubMed ID: 23332403
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ethics related to drug therapy in the elderly.
    Beglinger C
    Dig Dis; 2008; 26(1):28-31. PubMed ID: 18600011
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Use of midazolam as a human cytochrome P450 3A probe: I. In vitro-in vivo correlations in liver transplant patients.
    Thummel KE; Shen DD; Podoll TD; Kunze KL; Trager WF; Hartwell PS; Raisys VA; Marsh CL; McVicar JP; Barr DM
    J Pharmacol Exp Ther; 1994 Oct; 271(1):549-56. PubMed ID: 7965755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The hepatic sinusoid in aging and cirrhosis: effects on hepatic substrate disposition and drug clearance.
    Le Couteur DG; Fraser R; Hilmer S; Rivory LP; McLean AJ
    Clin Pharmacokinet; 2005; 44(2):187-200. PubMed ID: 15656697
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Changes in cytochrome P450s-mediated drug clearance in patients with hepatocellular carcinoma in vitro and in vivo: a bottom-up approach.
    Gao J; Zhou J; He XP; Zhang YF; Gao N; Tian X; Fang Y; Wen Q; Jia LJ; Jin H; Qiao HL
    Oncotarget; 2016 May; 7(19):28612-23. PubMed ID: 27086920
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prediction of Drug Clearance and Drug-Drug Interactions in Microscale Cultures of Human Hepatocytes.
    Lin C; Shi J; Moore A; Khetani SR
    Drug Metab Dispos; 2016 Jan; 44(1):127-36. PubMed ID: 26452722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lean body mass as a predictor of drug dosage. Implications for drug therapy.
    Morgan DJ; Bray KM
    Clin Pharmacokinet; 1994 Apr; 26(4):292-307. PubMed ID: 8013162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.